XML 12 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 1,418 $ 963
Trade receivables 6,289 7,128
Inventories 5,113 4,924
Prepaid expenses 1,138 1,100
Other current assets 712 701
Assets held for sale 17 566
Total current assets 14,687 15,382
Deferred income taxes 463 574
Other non-current assets 832 932
Property, plant and equipment, net 7,420 7,673
Identifiable intangible assets, net 17,314 17,640
Goodwill 28,465 28,414
Total assets 69,181 70,615
Current liabilities:    
Short-term debt 1,302 3,646
Sales reserves and allowances 7,410 7,881
Trade payables 1,929 2,069
Employee-related obligations 607 549
Accrued expenses 2,632 3,014
Other current liabilities 876 724
Liabilities held for sale   38
Total current liabilities 14,756 17,921
Long-term liabilities:    
Deferred income taxes 2,998 3,277
Other taxes and long-term liabilities 1,875 1,843
Senior notes and loans 29,450 28,829
Total long-term liabilities 34,323 33,949
Commitments and contingencies, see note 16
Total liabilities 49,079 51,870
Teva shareholders' equity:    
Preferred shares of NIS 0.10 par value per mandatory convertible preferred share; March 31, 2018 and December 31, 2017: authorized 5.0 million shares; issued 3.7 million shares 3,696 3,631
Ordinary shares of NIS 0.10 par value per share; March 31, 2018 and December 31, 2017: authorized 2,495 million shares; issued 1,124 million shares 54 54
Additional paid-in capital 23,443 23,479
Retained earnings (2,688) (3,808)
Accumulated other comprehensive loss (1,735) (1,848)
Treasury shares as of March 31, 2018 and December 31, 2017 -106 million ordinary shares and 107 million ordinary shares, respectively (4,149) (4,149)
Stockholders' equity attributable to Teva shareholders 18,621 17,359
Non-controlling interests 1,481 1,386
Total equity 20,102 18,745
Total liabilities and equity $ 69,181 $ 70,615